Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice

Ibrahim, Hany M.; Ghaffar, Faten R. Abdel; El-Elaimy, Ibrahim A.; Gouida, Mona S.; Latif, Heba M. Abd El

doi:10.1016/j.biopha.2018.06.113

Cited by 21 publications

(19 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The inhibition of cell proliferation was indicated as cytotoxicity of the substances. Previous studies revealed that TAU inhibited cell proliferation in various cancer cells, for example, colon cancer cells (Zhang et al, 2014;Liu et al, 2018), breast cancer cells (Zhang et al, 2015), lung cancer cells (Tu et al, 2018), nasopharyngeal carcinoma cells (He et al, 2018), Ehrlich ascites carcinoma (Ibrahim et al, 2018). In the present study, we found that TAU also inhibited cell proliferation in U-251 MG cells in a dose-dependent manner.…”

Section: Discussionsupporting

confidence: 75%

Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells

Surarak

Chantree

Sangpairoj

2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

22 (12), 4001-4009 is the most common brain tumor and has been found in people worldwide, including in Thailand (Miranda-Filho et al., 2017;Witthayanuwat et al., 2018). Major signs and symptoms of GBM include motor weakness in the beginning, progressive headache, and convulsion. Other signs and symptoms depend on brain areas that the tumor invades into such as hemiparesis, visual loss, and aphasia. The definite cause of this tumor is unknown; however, there are some theories proposed that it might cause by genetic factors, race or, people who have ever received radiation therapy on head-to-neck area (Urbańska et al., 2014). This disease has a poor prognosis, and its survival rate is approximately 13-16 months (Shergalis et al., 2018; Urbańska et al., 2014;Bleeker et al., 2012). The current standard treatments for GBM patients include

show abstract

Section: Discussionsupporting

confidence: 75%

Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells

Surarak

Chantree

Sangpairoj

2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Similarly, [Bet][Tau] also showed antitumor effects (Figure S17) and Table S5 summarizes the IC 50 of [Bet][Tau] and [Bet][Tau]/DOX against the Caco-2 cells. Therefore, these results indicated that Tau-based ILs have a significant killing effect on tumor cells. ,, …”

Section: Resultsmentioning

confidence: 73%

“…The dual therapy based on Lms and Tau efficiently reduced tumor growth by promoting apoptosis and regulating the immune response. Lms and Tau successfully enhanced the anticancer effect of chemotherapy and mitigated its adverse effects . Murata et al used a mouse model of colon cancer induced by azoxymethane/sodium sulfate to prove for the first time that Tau can significantly reduce carcinogenicity in vivo.…”

Section: Introductionmentioning

confidence: 99%

Taurine-Based Ionic Liquids for Transdermal Protein Delivery and Enhanced Anticancer Activity

Lü

et al. 2021

ACS Sustainable Chem. Eng.

View full text Add to dashboard Cite

Tumor is one of the most serious forms of abnormal growth that endangers human health today; its morbidity and mortality are both increasing every year. Most of the antitumor drugs used currently cannot be absorbed well by the human body because of their poor solubility and low bioavailability. Therefore, the prevention and treatment of tumors are still of high significance. These challenges can be addressed by the use of ionic liquids (ILs). Half of the antitumor drugs currently in the market are salts linked together by ILs. Compared to the solid form of the drug, the salt that is liquid at room temperature or body temperature shows good solubility, absorption, and stability. Therefore, in this study, we combined taurine with antitumor activity and alkaloids with biological activity (L-(−)-carnitine or betaine) to produce IL salts possessing the merits of both these components to develop an efficient and cost-effective drug delivery system for tumor treatment. Taurine-based ILs can deliver proteins such as insulin or dextran, which are promising drug delivery carriers. In vitro experiments showed that the taurine-based IL exhibited good biocompatibility, non-toxicity, and antitumor activity. Compared to the blank group, the proliferation inhibition rate of human colon adenocarcinoma cells (Caco-2) treated with different concentrations of taurine-based ILs increased significantly. The inhibitory effect of the taurine-based IL on Caco-2 cell proliferation became more pronounced with an increase in its concentration and the treatment time. Moreover, the results suggested that the combination of taurine-based ILs and chemotherapy drugs can improve the efficacy of chemotherapy drugs and reduce their adverse reactions. Interestingly, taurine-based ILs can inhibit the growth of tumor cells by inducing apoptosis in tumor cells after 4 h. This demonstrates the immense potential of taurine-based ILs in inhibiting the growth of tumor cells.

show abstract

“…Other small metabolites, such as vitamin D [ 279 ], taurine [ 280 ] and cysteine [ 281 ], also enhance antitumor immunity. Vitamin D regulates immune cell trafficking and differentiation, taurine alters the splenocyte immunological profile of CD3+ CD4+, CD3+ CD8+, CD4+ CD25+ and CD11b+ Ly6G+ cells to achieve better immune surveillance against tumor cells, and cysteine exerts a positive effect on T cell proliferation and activation.…”

Section: Noncoding Rnas Bridge Metabolites and Pro- Or Antitumor Immunitymentioning

confidence: 99%

Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers

et al. 2021

View full text Add to dashboard Cite

Altered metabolic patterns in tumor cells not only meet their own growth requirements but also shape an immunosuppressive microenvironment through multiple mechanisms. Noncoding RNAs constitute approximately 60% of the transcriptional output of human cells and have been shown to regulate numerous cellular processes under developmental and pathological conditions. Given their extensive action mechanisms based on motif recognition patterns, noncoding RNAs may serve as hinges bridging metabolic activity and immune responses. Indeed, recent studies have shown that microRNAs, long noncoding RNAs and circRNAs are widely involved in tumor metabolic rewiring, immune cell infiltration and function. Hence, we summarized existing knowledge of the role of noncoding RNAs in the remodeling of tumor metabolism and the immune microenvironment, and notably, we established the TIMELnc manual, which is a free and public manual for researchers to identify pivotal lncRNAs that are simultaneously correlated with tumor metabolism and immune cell infiltration based on a bioinformatic approach.

show abstract

Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice

Cited by 21 publications

References 60 publications

Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells

Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells

Taurine-Based Ionic Liquids for Transdermal Protein Delivery and Enhanced Anticancer Activity

Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers

Contact Info

Product

Resources

About